Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study'

被引：0
|
作者：
Zhu, Xudong [1 ,2 ]
机构：
[1] China Med Univ, Dalian Univ Technol, Liaoning Canc Hosp & Inst, Dept Gen Surg,Canc Hosp, Shenyang, Liaoning, Peoples R China
[2] Liaoning Prov Key Lab Precis Med Malignant Tumors, Shenyang, Liaoning, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2025年 / 13卷 / 03期
关键词：
Immunotherapy; Lung Cancer;
D O I：
10.1136/jitc-2025-011845
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Advanced non-small cell lung cancer - Treatment with Pembrolizumab
    Silvinato, Antonio
    Floriono, Idevaldo
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (12): : 1423 - 1432
  • [32] Real-World Brigatinib Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in the United States
    Lin, H.
    Wu, Y.
    Gorritz, M.
    Mcguiness, C.
    Huang, W.
    Chen, C.
    Ren, K.
    Camidge, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S661 - S661
  • [33] Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
    Matsumoto, Kinnosuke
    Shiroyama, Takayuki
    Tamiya, Motohiro
    Minami, Toshiyuki
    Kinehara, Yuhei
    Tamiya, Akihiro
    Suga, Yasuhiko
    Kuge, Tomoki
    Mori, Masahide
    Suzuki, Hidekazu
    Tobita, Satoshi
    Ueno, Kiyonobu
    Namba, Yoshinobu
    Tetsumoto, Satoshi
    Niki, Toshie
    Morimura, Osamu
    Osa, Akio
    Nishino, Kazumi
    Nagatomo, Izumi
    Takeda, Yoshito
    Kijima, Takashi
    Kumanogoh, Atsushi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (01)
  • [34] Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
    Kinnosuke Matsumoto
    Takayuki Shiroyama
    Motohiro Tamiya
    Toshiyuki Minami
    Yuhei Kinehara
    Akihiro Tamiya
    Yasuhiko Suga
    Tomoki Kuge
    Masahide Mori
    Hidekazu Suzuki
    Satoshi Tobita
    Kiyonobu Ueno
    Yoshinobu Namba
    Satoshi Tetsumoto
    Toshie Niki
    Osamu Morimura
    Akio Osa
    Kazumi Nishino
    Izumi Nagatomo
    Yoshito Takeda
    Takashi Kijima
    Atsushi Kumanogoh
    Cancer Immunology, Immunotherapy, 2024, 73
  • [35] Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in a real-world setting
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 161
  • [36] Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis
    Hardtstock, Fraence
    Myers, David
    Li, Tracy
    Cizova, Diana
    Maywald, Ulf
    Wilke, Thomas
    Griesinger, Frank
    BMC CANCER, 2020, 20 (01)
  • [37] Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis
    Fränce Hardtstock
    David Myers
    Tracy Li
    Diana Cizova
    Ulf Maywald
    Thomas Wilke
    Frank Griesinger
    BMC Cancer, 20
  • [38] The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
    Wang, F.
    Jin, F.
    Wang, S.
    Zhu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S673 - S673
  • [39] Real-World Data of Nivolumab for Previously Treated Non-Small Cell Lung Cancer Patients in Japan: A Multicenter Retrospective Cohort Study
    Fujimoto, D.
    Yoshioka, H.
    Kataoka, Y.
    Kim, Y.
    Tomii, K.
    Ishida, T.
    Hirabayashi, M.
    Hara, S.
    Ishitoko, M.
    Fukuda, Y.
    Hwang, M. H.
    Sakai, N.
    Fukui, M.
    Nakaji, H.
    Hirai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2424 - S2425
  • [40] A real-world study update: Efficacy and safety of anlotinib for advanced non-small cell lung cancer.
    Wang, Jinlin
    Yi, Tienan
    Dong, Youhong
    Xu, Xinhua
    Cao, Fengjun
    Ran, Ruizhi
    Yin, Yifa
    Li, Yinping
    Fu, Yang
    Xu, Yanhua
    Kuang, Li
    Chen, Guiming
    Qu, Guangqiao
    Li, Jun
    Luo, Zhiguo
    Chen, Yuan
    Song, Qibin
    Chu, Qian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345